Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/17/2017 02/21/2017 02/22/2017 02/23/2017 02/24/2017 Date
1.14(c) 1.1225(c) 1.14(c) 1.13(c) 1.12(c) Last
201 077 198 306 221 808 228 927 324 388 Volume
+0.88% -1.54% +1.56% -0.88% -0.88% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -29,3 M
Net income 2017 -29,2 M
Finance 2017 39 976 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -35,0 M
Net income 2018 -35,7 M
Debt 2018 194 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 108 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
02/13 Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2..
02/09 PLURISTEM THERAPEUTICS : reports 2Q loss
02/08 PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
01/27 PLURISTEM THERAPEUTICS : Announces Closing of Bought Offering and Underwriters E..
01/25 Pluristem Announces Closing of Bought Offering and Underwriter’s Exerci..
01/22 PLURISTEM THERAPEUTICS : raises $15m, Can-Fite raises $5m
01/22 PLURISTEM THERAPEUTICS : Increases Previously Announced Bought Deal Offering of ..
01/20 PLURISTEM THERAPEUTICS INC : Entry into a Material Definitive Agreement, Financi..
01/20 FRIDAY SECTOR LAGGARDS : Biotechnology, Aerospace & Defense Stocks
01/20 PLURISTEM THERAPEUTICS : Receives Clearance from Germany to Initiate Its Multina..
More news
Sector news : Biotechnology & Medical Research - NEC
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/22Will Pluristem's Acute Radiation Syndrome Trial Results In May Bring Some Pot.. 
02/15Zacks Investment Research Upgrades Pluristem Therapeutics, Inc. $PSTI to “Buy.. 
02/15Pluristem Therapeutics upgraded by Zacks Investment Research to buy. $1.25 PT.. 
02/13Pluristem Therapeutics downgraded by Maxim Group to hold.  
02/13$PSTI: Pluristem Therapeutics provides clinical updates; study initiation of .. 
More tweets
Qtime:11
News from SeekingAlpha
02/22 Will Pluristem's Acute Radiation Syndrome Trial Results In May Bring Some Pot..
01/20 Midday Gainers / Losers
01/20 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
01/20 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
01/20 Pluristem increases underwriting deal with Wainwright to $15M; shares down 17..
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Technical analysis trends PLURISTEM THERAPE...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,25 $
Spread / Average Target 190%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Zami Aberman Chairman & Chief Executive Officer
Yaky Yanay President, COO, CFO, Secretary & Director
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Mark S. Germain Director
Nachum Rosman Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS..-20.98%108
INCYTE CORPORATION21.62%24 852
QUINTILES IMS HOLDINGS..2.72%18 301
CELLTRION, INC.--.--%10 911
LONZA GROUP AG2.67%10 319
SEATTLE GENETICS, INC.19.52%8 939
More Results